Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 + T cell activation and HIV-1 latency reversal | Zendy

Shijie Cao | Zendy; Sarah D. Slack | Zendy; Claire Levy | Zendy; Sean M. Hughes | Zendy; Yonghou Jiang | Zendy; Christopher Yogodzinski | Zendy; Pavitra Roychoudhury | Zendy; Keith R. Jerome | Zendy; Joshua T. Schiffer | Zendy; Florian Hladik | Zendy; Kim A. Woodrow | Zendy

Open Access

Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 ⁺ T cell activation and HIV-1 latency reversal

Author(s) -

Shijie Cao,

Sarah D. Slack,

Claire Levy,

Sean M. Hughes,

Yonghou Jiang,

Christopher Yogodzinski,

Pavitra Roychoudhury,

Keith R. Jerome,

Joshua T. Schiffer,

Florian Hladik,

Kim A. Woodrow

Publication year - 2019

Publication title -

science advances

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.aav6322

Subject(s) - nanocarriers , latency (audio) , lymph , reversing , human immunodeficiency virus (hiv) , lymphatic system , cancer research , lentivirus , chemistry , immunology , microbiology and biotechnology , medicine , pharmacology , biology , drug , materials science , computer science , pathology , telecommunications , viral disease , composite material

Targeted nanocarriers deliver HIV-1 latency-reversing agents to CD4+ T cells in the lymph nodes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research